Tarsus Pharmaceuticals, Inc. — Director's Dealing 2026

Feb 20, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2026-02-18

Reporting Person: PYOTT DAVID E I (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-02-18	Stock Option (right to buy)	$63.27	A	5893	Acquired	2036-02-17	Common Stock (5893)	Direct
2026-02-18	Restricted Stock Units	$	A	3729	Acquired		Common Stock (3729)	Direct

Footnotes

F1: The option shares will vest in three equal annual installments on February 18th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3: The RSUs will vest in three equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.